AUPH - Aurinia Pharmaceuticals Stock Price, News & Analysis

$5.27 0.16 (3.13 %)
(As of 11/24/2017 02:21 AM ET)
Previous Close$5.11
Today's Range$5.08 - $5.32
52-Week Range$2.02 - $10.54
Volume696,400 shs
Average Volume3.76 million shs
Market Capitalization$429.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49

About Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AUPH
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio26.99%
Quick Ratio26.99%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$170,000.00
Price / Sales2,603.07
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book2.64

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.32)
Net Income$-23,290,000.00
Net Margins-18,089.02%
Return on Equity-25.56%
Return on Assets-20.72%

Miscellaneous

Employees20
Outstanding Shares83,970,000

Frequently Asked Questions for Aurinia Pharmaceuticals (NASDAQ:AUPH)

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02. The biotechnology company earned $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The company's revenue for the quarter was up .0% on a year-over-year basis. View Aurinia Pharmaceuticals' Earnings History.

When will Aurinia Pharmaceuticals make its next earnings announcement?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Aurinia Pharmaceuticals.

Where is Aurinia Pharmaceuticals' stock going? Where will Aurinia Pharmaceuticals' stock price be in 2017?

6 brokers have issued 1-year price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $12.00 in the next year. View Analyst Ratings for Aurinia Pharmaceuticals.

What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (11/17/2017)
  • 2. FBR & Co analysts commented, "We increase our price target 22% from $9 to $11, as we think that with a balance sheet bolstered by a public offering that we estimate raised up to $161M in net proceeds, AUPH is now in a strong position to independently advance voclosporin (VCS), its investigational therapy for patients with active lupus nephritis (LN), into Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by major pharmaceutical companies (Big Pharma) hungry for the next multi-billiondollar drug (FBR projects VCS could achieve >$2B in annual peak sales), we look for AUPH to receive an acquisition bid from a Big Pharma company in the next six to nine months, with an initial bid of $10 per share reasonable. We think AUPH is more likely to look to sign a partnership agreement; therefore, we look for a deal worth $500M to $700M in up-front and milestone payments to AUPH. We reiterate our Outperform rating." (3/22/2017)

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 11,398,745 shares, an increase of 13.7% from the October 13th total of 10,028,331 shares. Based on an average daily trading volume, of 1,861,050 shares, the days-to-cover ratio is currently 6.1 days. Currently, 23.6% of the company's shares are sold short.

Who are some of Aurinia Pharmaceuticals' key competitors?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:

  • Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer (Age 57)
  • Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
  • Michael R. Martin, Chief Operating Officer
  • Neil Solomons M.D., Chief Marketing Officer
  • Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
  • Robert B. Huizinga, Vice President - Clinical Affairs
  • Lawrence D. Mandt, Vice President - Regulatory and Quality (Age 57)
  • George M. Milne Jr., Ph.D., Director (Age 73)
  • Lorin Jeffry Randall, Director (Age 73)
  • Benjamin Rovinski Ph.D., Independent Director (Age 58)

Who owns Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Alyeska Investment Group L.P. (0.82%), Ameriprise Financial Inc. (0.25%), Ironwood Investment Management LLC (0.23%), Investment Centers of America Inc. (0.07%), Cutler Capital Management LLC (0.05%) and Wells Fargo & Company MN (0.03%). View Institutional Ownership Trends for Aurinia Pharmaceuticals.

Who bought Aurinia Pharmaceuticals stock? Who is buying Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Ironwood Investment Management LLC, Investment Centers of America Inc., Wells Fargo & Company MN, Alyeska Investment Group L.P. and Cutler Capital Management LLC. View Insider Buying and Selling for Aurinia Pharmaceuticals.

How do I buy Aurinia Pharmaceuticals stock?

Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $5.27.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $429.10 million and generates $170,000.00 in revenue each year. The biotechnology company earns $-23,290,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Aurinia Pharmaceuticals employs 20 workers across the globe.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is #1203-4464 Markham Street, Victoria A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]


MarketBeat Community Rating for Aurinia Pharmaceuticals (AUPH)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aurinia Pharmaceuticals (NASDAQ:AUPH)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (127.70% upside)

Consensus Price Target History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Price Target History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Analysts' Ratings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017Canaccord GenuitySet Price TargetBuy$11.00N/AView Rating Details
11/15/2017HC WainwrightReiterated RatingBuy$12.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetOutperform$10.00 -> $14.00N/AView Rating Details
10/23/2017Cantor FitzgeraldReiterated RatingBuy$14.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$10.00N/AView Rating Details
4/11/2017FBR & CoReiterated RatingOutperformMediumView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
11/2/2016MackieReiterated RatingBuy$8.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Earnings by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Earnings History by Quarter for Aurinia Pharmaceuticals (NASDAQ AUPH)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
11/14/2017n/a($0.14)($0.16)$0.03 million$0.03 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.13)($0.03)$0.06 million$0.33 millionViewN/AView Earnings Details
5/15/20173/31/2017($0.12)($0.20)$0.05 million$0.03 millionViewN/AView Earnings Details
3/9/2017Q4($0.12)($0.22)$0.06 million$0.03 millionViewN/AView Earnings Details
5/11/2016Q1($0.14)($0.13)$0.10 million$0.06 millionViewN/AView Earnings Details
3/18/2016Q4($0.16)($0.16)$0.09 million$0.06 millionViewN/AView Earnings Details
3/30/2015Q4 2014($0.11)($0.15)$0.10 million$0.07 millionViewN/AView Earnings Details
11/12/2014Q3 14($0.08)$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)
2017 EPS Consensus Estimate: ($0.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.13)($0.10)($0.12)
Q2 20172($0.13)($0.11)($0.12)
Q3 20172($0.14)($0.12)($0.13)
Q4 20172($0.17)($0.08)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (NASDAQ AUPH)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Aurinia Pharmaceuticals (NASDAQ AUPH)

Source:
DateHeadline
Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Recommendation of "Buy" by BrokeragesAurinia Pharmaceuticals Inc (AUPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 23 at 10:10 AM
Cantor Fitzgerald Weighs in on Aurinia Pharmaceuticals Incs FY2017 Earnings (AUPH)Cantor Fitzgerald Weighs in on Aurinia Pharmaceuticals Inc's FY2017 Earnings (AUPH)
www.americanbankingnews.com - November 22 at 6:44 AM
Analysts Issue Forecasts for Aurinia Pharmaceuticals Incs FY2017 Earnings (AUPH)Analysts Issue Forecasts for Aurinia Pharmaceuticals Inc's FY2017 Earnings (AUPH)
www.americanbankingnews.com - November 17 at 9:44 PM
FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Decreased by Analyst (AUPH)FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Decreased by Analyst (AUPH)
www.americanbankingnews.com - November 17 at 9:44 PM
Aurinia Pharmaceuticals Inc (AUPH) Downgraded by Zacks Investment Research to SellAurinia Pharmaceuticals Inc (AUPH) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 17 at 7:58 PM
Aurinia Pharmaceuticals Inc (AUPH) PT Set at $11.00 by Canaccord GenuityAurinia Pharmaceuticals Inc (AUPH) PT Set at $11.00 by Canaccord Genuity
www.americanbankingnews.com - November 17 at 10:38 AM
Aurinia Has Canaccord Captivated with Voclosporin ProspectsAurinia Has Canaccord Captivated with Voclosporin Prospects
finance.yahoo.com - November 17 at 10:00 AM
H.C. Wainwright Likes Aurinia Pharmaceuticals’ Opportunity at Hand in the Lupus Nephritis MarketH.C. Wainwright Likes Aurinia Pharmaceuticals’ Opportunity at Hand in the Lupus Nephritis Market
finance.yahoo.com - November 16 at 4:27 PM
Aurinia reports 3Q lossAurinia reports 3Q loss
finance.yahoo.com - November 16 at 4:27 PM
Aurinia Pharmaceuticals (AUPH) "Buy" Rating Reaffirmed at HC WainwrightAurinia Pharmaceuticals' (AUPH) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 15 at 1:52 PM
After-Hours Earnings Report for November 14, 2017 : YY, MTSI, ESE, BOLD, BZH, YRD, ARA, AUPH, SLP, FOMX ... - NasdaqAfter-Hours Earnings Report for November 14, 2017 : YY, MTSI, ESE, BOLD, BZH, YRD, ARA, AUPH, SLP, FOMX ... - Nasdaq
www.nasdaq.com - November 14 at 9:41 PM
Aurinia Pharmaceuticals Inc (AUPH) Announces  Earnings Results, Misses Estimates By $0.02 EPSAurinia Pharmaceuticals Inc (AUPH) Announces Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - November 14 at 9:34 PM
Aurinia Pharmaceuticals Inc. to Host Earnings CallAurinia Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - November 14 at 4:38 PM
What Does Aurinia Pharmaceuticals Inc’s (TSX:AUP) Share Price Indicate?What Does Aurinia Pharmaceuticals Inc’s (TSX:AUP) Share Price Indicate?
finance.yahoo.com - November 14 at 4:38 PM
Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational HighlightsAurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights
finance.yahoo.com - November 14 at 4:38 PM
Aurinia Pharmaceuticals Inc (AUPH) Short Interest Up 13.7% in OctoberAurinia Pharmaceuticals Inc (AUPH) Short Interest Up 13.7% in October
www.americanbankingnews.com - November 11 at 3:40 AM
Aurinia Pharmaceuticals: Research, Cash Flow Projections, And 2020 Price Targets - Seeking AlphaAurinia Pharmaceuticals: Research, Cash Flow Projections, And 2020 Price Targets - Seeking Alpha
seekingalpha.com - November 10 at 1:16 PM
Aurinia Pharmaceuticals Inc (AUPH) Set to Announce Quarterly Earnings on TuesdayAurinia Pharmaceuticals Inc (AUPH) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 8 at 10:14 AM
Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Quarterly Sales of $130,000.00Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Quarterly Sales of $130,000.00
www.americanbankingnews.com - November 8 at 9:33 AM
Lightning Round: Jim Cramer Gives His Opinion On Aurinia, GameStop, And MoreLightning Round: Jim Cramer Gives His Opinion On Aurinia, GameStop, And More
www.benzinga.com - November 6 at 10:14 PM
Jim Cramer Gives His Opinion On Aurinia, GameStop, And More ... - BenzingaJim Cramer Gives His Opinion On Aurinia, GameStop, And More ... - Benzinga
www.benzinga.com - November 6 at 5:12 PM
Lightning Round: Jim Cramer Gives His Opinion On Aurinia, GameStop, And More - BenzingaLightning Round: Jim Cramer Gives His Opinion On Aurinia, GameStop, And More - Benzinga
www.benzinga.com - November 6 at 5:12 PM
Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017
finance.yahoo.com - November 6 at 5:12 PM
Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017
finance.yahoo.com - November 6 at 5:12 PM
Zacks: Brokerages Anticipate Aurinia Pharmaceuticals Inc (AUPH) Will Post Earnings of -$0.15 Per ShareZacks: Brokerages Anticipate Aurinia Pharmaceuticals Inc (AUPH) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - November 6 at 9:59 AM
Aurinia Pharmaceuticals (AUPH) PT Raised to $12 at HC Wainwright; R&D Day Showcases New Indications ... - StreetInsider.comAurinia Pharmaceuticals (AUPH) PT Raised to $12 at HC Wainwright; 'R&D Day Showcases New Indications ... - StreetInsider.com
www.streetinsider.com - October 30 at 5:09 PM
HC Wainwright Reaffirms Buy Rating for Aurinia Pharmaceuticals Inc (AUPH)HC Wainwright Reaffirms Buy Rating for Aurinia Pharmaceuticals Inc (AUPH)
www.americanbankingnews.com - October 30 at 8:23 AM
Aurinia Pharmaceuticals Inc (AUPH) Receives Average Rating of "Buy" from BrokeragesAurinia Pharmaceuticals Inc (AUPH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 29 at 5:38 AM
Aurinia Pharmaceuticals Inc (AUPH) Lowered to "Hold" at Zacks Investment ResearchAurinia Pharmaceuticals Inc (AUPH) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 24 at 8:00 PM
Aurinia Pharmaceuticals Inc (AUPH) Stock Rating Reaffirmed by Cantor FitzgeraldAurinia Pharmaceuticals Inc (AUPH) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - October 23 at 8:46 PM
Leerink Swann Boosts Aurinia Pharmaceuticals Inc (AUPH) Price Target to $14.00Leerink Swann Boosts Aurinia Pharmaceuticals Inc (AUPH) Price Target to $14.00
www.americanbankingnews.com - October 23 at 4:24 PM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : October 23, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : October 23, 2017
finance.yahoo.com - October 23 at 3:57 PM
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye SyndromeAurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome
finance.yahoo.com - October 20 at 6:01 PM
Aurinia Pharmaceuticals Inc (AUPH) Announces Clinical Development for New IndicationsAurinia Pharmaceuticals Inc (AUPH) Announces Clinical Development for New Indications
finance.yahoo.com - October 20 at 6:00 PM
 Analysts Expect Aurinia Pharmaceuticals Inc (AUPH) Will Announce Quarterly Sales of $130,000.00 Analysts Expect Aurinia Pharmaceuticals Inc (AUPH) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - October 19 at 8:18 AM
Aurinia Pharmaceuticals: An Under $10 Biotech Stock To Keep An Eye On - Seeking AlphaAurinia Pharmaceuticals: An Under $10 Biotech Stock To Keep An Eye On - Seeking Alpha
seekingalpha.com - October 17 at 3:08 AM
Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?
finance.yahoo.com - October 16 at 5:02 PM
Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in SessionAurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
finance.yahoo.com - October 16 at 5:02 PM
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock OptionsImplied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
finance.yahoo.com - October 16 at 5:02 PM
Comparing Aurinia Pharmaceuticals (AUPH) & Akebia Therapeutics (AKBA)Comparing Aurinia Pharmaceuticals (AUPH) & Akebia Therapeutics (AKBA)
www.americanbankingnews.com - October 13 at 12:26 AM
Aurinia Receives National Corporate Visionary Award from the ... - Business Wire (press release)Aurinia Receives National Corporate Visionary Award from the ... - Business Wire (press release)
www.businesswire.com - October 12 at 5:01 PM
Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of AmericaAurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
finance.yahoo.com - October 12 at 5:01 PM
Aurinia Pharmaceuticals Inc (AUPH) Now Covered by Analysts at Seaport Global SecuritiesAurinia Pharmaceuticals Inc (AUPH) Now Covered by Analysts at Seaport Global Securities
www.americanbankingnews.com - October 7 at 2:58 PM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : September 29, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : September 29, 2017
finance.yahoo.com - October 2 at 4:06 PM
Aurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : October 2, 2017Aurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : October 2, 2017
finance.yahoo.com - October 2 at 4:06 PM
Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Quarterly Sales of $60,000.00Aurinia Pharmaceuticals Inc (AUPH) Expected to Post Quarterly Sales of $60,000.00
www.americanbankingnews.com - October 1 at 3:22 PM
Aurinia Pharma (AUPH) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - SlideshowAurinia Pharma (AUPH) Presents At LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology - Slideshow
seekingalpha.com - September 28 at 4:37 PM
Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors - Motley FoolWhy Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors - Motley Fool
www.fool.com - September 28 at 12:57 AM
Aurinia Pharma (AUPH) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowAurinia Pharma (AUPH) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 7:47 PM
Aurinia Pharmaceuticals Inc (AUPH) Stock Rating Upgraded by Vetr Inc.Aurinia Pharmaceuticals Inc (AUPH) Stock Rating Upgraded by Vetr Inc.
www.americanbankingnews.com - September 24 at 2:44 PM

Social Media

Financials

Chart

Aurinia Pharmaceuticals (NASDAQ AUPH) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.